MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517071012 A) filed by Voyager Therapeutics, Inc., Lexington, U.S.A., on July 25, for 'compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta 1 deficiency.'
Inventor(s) include Chung, Hiu Yan; Knoll, Elisabeth; and Carter, Todd.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and/or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson's Disease (PD), Gaucher Disease (GD), Dementia with Lewy Bodies (DLB), or related condition resulting from a deficiency in the quantity and/or function of GBA1 gene product or associated with decreased expression or protein levels of GCase protein."
The patent application was internationally filed on Feb. 01, 2024, under International application No.PCT/US2024/014000.
Disclaimer: Curated by HT Syndication.
